Supplement Scholar
Mineral

Zinc Picolinate

Buy on Amazon ↗

Affiliate link: we may earn a commission at no extra cost to you. Disclosures

Zinc Picolinate. Zinc chelated to picolinic acid — one of the most bioavailable oral forms.

How it works. Picolinic acid is a natural zinc transporter secreted by the pancreas — bypasses competition with other divalent cations.

What the research supports. 1 graded claims. Strongest: Highest serum Zn rise vs other oral forms in small comparison (limited).

How much to take. Typical dose: 15–30 mg elemental.

Side effects and interactions. 1 medication interaction listed. Serious: Copper deficiency at >40 mg/d long-term.

Stacking. Pairs well with Copper.

Common forms. Available as Chelated form (glycinate, bisglycinate, citrate, malate), Inorganic salt (oxide, sulfate, chloride), Liquid ionic solution, Topical or transdermal preparation.

Key studies. 8 studies cited. The strongest are listed with links to PubMed.

Community. Experiences from people who have tried Zinc Picolinate. Anecdotes are not medical advice.

Zinc Picolinate. Zinc chelated to picolinic acid — one of the most bioavailable oral forms.

Molecular structureC12H8N2O4Zn · 309.6 g/mol

What it is

Zinc chelated to picolinic acid — one of the most bioavailable oral forms.

Food sources

Whole foods (leafy greens, legumes, nuts, seeds, seafood, animal proteins)Fortified foods such as cereals, breads, plant milks, and table saltMineral supplements as chelates, citrates, glycinates, or inorganic salts

Goals

How it works

Picolinic acid is a natural zinc transporter secreted by the pancreas — bypasses competition with other divalent cations.

Pathways

  • Zn-finger transcription factors
  • 5α-reductase modulation
  • Antioxidant (SOD1)

Effects

  • +Highest serum Zn rise vs other oral forms in small comparison supports

What the research supports

Highest serum Zn rise vs other oral forms in small comparisonlimited

Strong: consistent results across large trials or meta-analyses. Moderate: several trials, mostly positive. Limited: small or mixed studies. Preclinical: animal or cell research only.

Typical dose
15–30 mg elemental
TimingConsistent daily timing recommended; split larger doses if GI tolerance is a concern.
With foodWith food
Best formMost evidence is based on the chelated form (glycinate, bisglycinate, citrate, malate) form.
Upper limit40 mg/d UL
Shop Zinc Picolinate on Amazon ↗

As an Amazon Associate I earn from qualifying purchases. Look for USP, NSF or Informed Sport seals before you buy.

Side effects & interactions

Common side effects

  • Nausea on empty stomach

Serious

  • Copper deficiency at >40 mg/d long-term

Medication interactions

Prescription medications (general)minor

Always disclose Zinc Picolinate use to your prescriber — additive, antagonistic, or pharmacokinetic interactions are possible.

Check any supplement–medication combination with your pharmacist before starting.

Combines with

Pairs well

  • CopperPrevents long-term copper deficiency.

Common forms

  • Chelated form (glycinate, bisglycinate, citrate, malate)
  • Inorganic salt (oxide, sulfate, chloride)
  • Liquid ionic solution
  • Topical or transdermal preparation

Key studies

8 studies cited in total.

PubMed: Zinc Picolinate — Highest serum Zn rise vs other oral forms in small comparison ↗
Systematic review · PubMed (NLM) · 2026

Opens current human and preclinical literature matching Zinc Picolinate and "Highest serum Zn rise vs other oral forms in small comparison". Filter by RCT, meta-analysis, or year on the results page.

PubMed: Zinc Picolinate — randomized controlled trial ↗
Systematic review · PubMed (NLM) · 2026

Opens current human and preclinical literature matching Zinc Picolinate and "randomized controlled trial". Filter by RCT, meta-analysis, or year on the results page.

PubMed: Zinc Picolinate — meta-analysis ↗
Systematic review · PubMed (NLM) · 2026

Opens current human and preclinical literature matching Zinc Picolinate and "meta-analysis". Filter by RCT, meta-analysis, or year on the results page.

Discussion

Loading discussion…